Australia · Delayed Price · Currency is AUD · OptionAlterity Therapeutics Company Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease.
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy.
The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.
Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
| Country | Australia |
| Founded | 1997 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 9 |
| CEO | David Stamler |
Contact Details
Address: 350 Collins Street Melbourne, 3000 Australia | |
| Phone | 61 3 9349 4906 |
| Website | alteritytherapeutics.com |
Stock Details
| Ticker Symbol | ATHO |
| Exchange | Australian Securities Exchange |
| Stock Type | Option |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Stamler | Chief Executive Officer |
| Abby Macnish Niven | Chief Financial Officer |